Slow the Spread. In the mouse brain, phospho-synuclein pathology (green) accumulates (top) in, from left to right, the motor ...

Researchers visualize α-synuclein pathology in living patients with a neurodegenerative disorder The National Institutes for Quantum Science and Technology Journal Movement Disorders DOI 10.1002 ...

MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) is set to participate in the 13th Alzheimer’s & Parkinson’s Drug Development ...

This article originally appeared in Research Colorado.Research at the University of Denver is showing promise for the ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies ...

The dbl-PAC-Tg(SNCA A53T) +/+;Snca-/-model, referred to here as double-transgenic mice, are mice lacking endogenous α-synuclein (Snca knockout mice) that were crossed with two homozygous transgenic ...

The assay for a particular abnormal form of the protein alpha-synuclein – known as αSyn-SAA – could also be used to diagnose people with Parkinson’s more quickly, help identify the best ...

This could assign a potential function to the synuclein family, which may have important implications for understanding the pathophysiology of neurodegenerative diseases.

This recent study highlights the neuroprotective potential of TFE3, a transcription factor that plays a pivotal role in counteracting key pathological mechanisms associated with Parkinson's disease ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment ...